News
GI Bleeding Up for New Users of Rivaroxaban
Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation
Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use
Risks for ischemic stroke or systemic embolism, major bleeding events lower with DOACs overall as a class versus warfarin